-
2
-
-
84891372505
-
Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study
-
De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol 2014, 15:23-34.
-
(2014)
Lancet Oncol
, vol.15
, pp. 23-34
-
-
De Angelis, R.1
Sant, M.2
Coleman, M.P.3
-
3
-
-
80051913984
-
2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference
-
Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011, 21:750-755.
-
(2011)
Int J Gynecol Cancer
, vol.21
, pp. 750-755
-
-
Stuart, G.C.1
Kitchener, H.2
Bacon, M.3
-
4
-
-
85013312416
-
Tumor angiogenesis: therapeutic implications
-
Folkman J Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
-
(1971)
N Engl J Med
, vol.285
, pp. 1182-1186
-
-
Folkman, J.1
-
5
-
-
84855425106
-
Incorporation of bevacizumab in the primary treatment of ovarian cancer
-
Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011, 365:2473-2483.
-
(2011)
N Engl J Med
, vol.365
, pp. 2473-2483
-
-
Burger, R.A.1
Brady, M.F.2
Bookman, M.A.3
-
6
-
-
84855466019
-
A Phase 3 trial of bevacizumab in ovarian cancer
-
Perren TJ, Swart AM, Pfisterer J, et al. A Phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011, 365:2484-2496.
-
(2011)
N Engl J Med
, vol.365
, pp. 2484-2496
-
-
Perren, T.J.1
Swart, A.M.2
Pfisterer, J.3
-
7
-
-
84861736119
-
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
-
Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012, 30:2039-2045.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2039-2045
-
-
Aghajanian, C.1
Blank, S.V.2
Goff, B.A.3
-
8
-
-
84899837376
-
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial
-
Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014, 32:1302-1308.
-
(2014)
J Clin Oncol
, vol.32
, pp. 1302-1308
-
-
Pujade-Lauraine, E.1
Hilpert, F.2
Weber, B.3
-
9
-
-
84938207508
-
-
The Electronic Medicines Compendium, (accessed Nov 18, 2014).
-
Avastin 25mg/ml concentrate for solution for infusion The Electronic Medicines Compendium, (accessed Nov 18, 2014). https://www.medicines.org.uk/emc/medicine/15748/SPC/Avastin+25mg+ml+concentrate+for+solution+for+infusion/.
-
Avastin 25mg/ml concentrate for solution for infusion
-
-
-
10
-
-
84938211289
-
-
US Food and Drug Administration, (accessed Nov 18, 2014).
-
Bevacizumab solution in combination with paclitaxel US Food and Drug Administration, (accessed Nov 18, 2014). http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm423159.htm.
-
Bevacizumab solution in combination with paclitaxel
-
-
-
11
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
12
-
-
0037102914
-
Flexible poportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects
-
Royston P, Parmar MKB Flexible poportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 2002, 21:2175-2197.
-
(2002)
Stat Med
, vol.21
, pp. 2175-2197
-
-
Royston, P.1
Parmar, M.K.B.2
-
13
-
-
84894044956
-
Late breaking abstract: final overall survival (OS) results from AURELIA, an open-label randomised phase III trial of chemotherapy (CT) with or without bevacizumab (BEV) for platinum-resistant recurrent ovarian cancer (OC)
-
Witteveen P, Lortholary A, Fehm T, et al. Late breaking abstract: final overall survival (OS) results from AURELIA, an open-label randomised phase III trial of chemotherapy (CT) with or without bevacizumab (BEV) for platinum-resistant recurrent ovarian cancer (OC). Eur J Cancer 2013, 49(suppl 3):S3-S4.
-
(2013)
Eur J Cancer
, vol.49
, pp. S3-S4
-
-
Witteveen, P.1
Lortholary, A.2
Fehm, T.3
-
14
-
-
84938098476
-
A phase III randomised controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (GOG-0213)
-
Coleman R, Brady M, Herzog T, et al. A phase III randomised controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (GOG-0213). Gynecol Oncol 2015, 137(suppl 1):3.
-
(2015)
Gynecol Oncol
, vol.137
, pp. 3
-
-
Coleman, R.1
Brady, M.2
Herzog, T.3
-
15
-
-
84871720057
-
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
-
Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013, 14:29-37.
-
(2013)
Lancet Oncol
, vol.14
, pp. 29-37
-
-
Bennouna, J.1
Sastre, J.2
Arnold, D.3
-
16
-
-
84908126746
-
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial
-
von Minckwitz G, Puglisi F, Cortes J, et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol 2014, 15:1269-1278.
-
(2014)
Lancet Oncol
, vol.15
, pp. 1269-1278
-
-
von Minckwitz, G.1
Puglisi, F.2
Cortes, J.3
-
17
-
-
70349878651
-
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
-
Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009, 374:1331-1338.
-
(2009)
Lancet
, vol.374
, pp. 1331-1338
-
-
Katsumata, N.1
Yasuda, M.2
Takahashi, F.3
-
18
-
-
84897380455
-
Phase III trial of every-3-weeks paclitaxel vs. dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262
-
Chan J, Brady M, Penson R, et al. Phase III trial of every-3-weeks paclitaxel vs. dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262. Int J Gynecol Cancer 2013, 23(8 suppl 1):9-10.
-
(2013)
Int J Gynecol Cancer
, vol.23
, Issue.8 SUPPL 1
, pp. 9-10
-
-
Chan, J.1
Brady, M.2
Penson, R.3
-
19
-
-
84875248912
-
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
-
Stark D, Nankivell M, Pujade-Lauraine P, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol 2013, 14:236-243.
-
(2013)
Lancet Oncol
, vol.14
, pp. 236-243
-
-
Stark, D.1
Nankivell, M.2
Pujade-Lauraine, P.3
-
20
-
-
84884562902
-
Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection
-
Collinson F, Hutchinson M, Craven RA, et al. Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. Clin Cancer Res 2013, 19:5227-5239.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 5227-5239
-
-
Collinson, F.1
Hutchinson, M.2
Craven, R.A.3
-
21
-
-
84964314560
-
The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer
-
Backen A, Renehan AG, Clamp AR, et al. The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer. Clin Cancer Res 2014, 20:4549-4558.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 4549-4558
-
-
Backen, A.1
Renehan, A.G.2
Clamp, A.R.3
-
22
-
-
84908319663
-
Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab
-
Gourley C, McCavigan A, Perren T, et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. Proc Am Soc Clin Oncol 2014, 32(5 suppl). abstr 5502.
-
(2014)
Proc Am Soc Clin Oncol
, vol.32
, Issue.5
-
-
Gourley, C.1
McCavigan, A.2
Perren, T.3
-
23
-
-
84903543603
-
Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer
-
Winterhoff BJN, Kommoss S, Oberg A, et al. Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer. Proc Am Soc Clin Oncol 2014, 32(5 suppl). abstr 5509.
-
(2014)
Proc Am Soc Clin Oncol
, vol.32
, Issue.5
-
-
Winterhoff, B.J.N.1
Kommoss, S.2
Oberg, A.3
|